{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:25:41Z","timestamp":1793147141086,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cisplatin resistance represents a major clinical challenge in small-cell lung cancer (SCLC), yet the underlying metabolic adaptations remain poorly understood. Here, we identify a novel regulatory axis centered on the fatty acid oxidation (FAO) enzyme carnitine palmitoyltransferase 1\u2009A (\n                    <jats:italic>CPT1A<\/jats:italic>\n                    ) that governs mitochondrial dynamics to drive chemoresistance. In cisplatin-resistant SCLC,\n                    <jats:italic>CPT1A<\/jats:italic>\n                    is markedly upregulated and undergoes functional acetylation. This modified CPT1A not only sustains cellular bioenergetics and redox balance through enhanced FAO but also directly recruits dynamin-related protein 1 (DRP1) to mitochondria. By facilitating DRP1-dependent mitochondrial fission, CPT1A orchestrates a metabolic adaptation that confers a survival advantage. Genetic or pharmacological inhibition of\n                    <jats:italic>CPT1A<\/jats:italic>\n                    reversed this phenotype, impairing mitochondrial fission, depleting energy stores, and resensitizing resistant cells to cisplatin. In vivo, targeting\n                    <jats:italic>CPT1A<\/jats:italic>\n                    markedly suppressed tumor growth and restored cisplatin sensitivity. Our results uncover an acetylated CPT1A-DRP1 axis as a critical metabolic vulnerability in cisplatin-resistant SCLC, providing a compelling therapeutic strategy to overcome treatment failure.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08868-x","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:25:41Z","timestamp":1779981941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CPT1A drives cisplatin resistance via acetylation\u2011dependent activation of DRP1 and mitochondrial fission in small cell lung cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Kuanbing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-4347","authenticated-orcid":false,"given":"Kefeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3548-7266","authenticated-orcid":false,"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"8868_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"8868_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Prim. 2021;7:3.","journal-title":"Nat Rev Dis Prim"},{"key":"8868_CR3","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869\u201383.","journal-title":"Oncogene"},{"key":"8868_CR4","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","volume":"368","author":"L Friboulet","year":"2013","unstructured":"Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368:1101\u201310.","journal-title":"N Engl J Med"},{"key":"8868_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrc3483","volume":"13","author":"A Carracedo","year":"2013","unstructured":"Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer. 2013;13:227\u201332.","journal-title":"Nat Rev Cancer"},{"key":"8868_CR6","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1158\/0008-5472.CAN-08-3722","volume":"69","author":"I Samudio","year":"2009","unstructured":"Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res. 2009;69:2163\u20136.","journal-title":"Cancer Res"},{"key":"8868_CR7","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.celrep.2016.02.004","volume":"14","author":"JH Park","year":"2016","unstructured":"Park JH, Vithayathil S, Kumar S, Sung P-L, Dobrolecki LE, Putluri V, et al. Fatty acid oxidation-driven Src links mitochondrial energy reprogramming and oncogenic properties in triple-negative breast cancer. Cell Rep. 2016;14:2154\u201365.","journal-title":"Cell Rep"},{"key":"8868_CR8","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1056\/NEJMc1400243","volume":"370","author":"SL Archer","year":"2014","unstructured":"Archer SL. Mitochondrial fission and fusion in human diseases. N Engl J Med. 2014;370:1074.","journal-title":"N Engl J Med"},{"key":"8868_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cmet.2017.05.016","volume":"26","author":"H Chen","year":"2017","unstructured":"Chen H, Chan DC. Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. Cell Metab. 2017;26:39\u201348.","journal-title":"Cell Metab"},{"key":"8868_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.molcel.2015.01.002","volume":"57","author":"JA Kashatus","year":"2015","unstructured":"Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol cell. 2015;57:537\u201351.","journal-title":"Mol cell"},{"key":"8868_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/febs.14186","volume":"285","author":"A Pe\u00f1a-Blanco","year":"2018","unstructured":"Pe\u00f1a-Blanco A, Garc\u00eda-S\u00e1ez AJ. Bax, Bak and beyond\u2014mitochondrial performance in apoptosis. FEBS J. 2018;285:416\u201331.","journal-title":"FEBS J"},{"key":"8868_CR12","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41418-022-00974-5","volume":"29","author":"X Xiong","year":"2022","unstructured":"Xiong X, Hasani S, Young LEA, Rivas DR, Skaggs AT, Martinez R, et al. Activation of Drp1 promotes fatty acids-induced metabolic reprograming to potentiate Wnt signaling in colon cancer. Cell Death Differ. 2022;29:1913\u201327.","journal-title":"Cell Death Differ"},{"key":"8868_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1161\/CIRCRESAHA.119.315252","volume":"126","author":"Q Hu","year":"2020","unstructured":"Hu Q, Zhang H, Guti\u00e9rrez Cort\u00e9s N, Wu D, Wang P, Zhang J, et al. Increased Drp1 acetylation by lipid overload induces cardiomyocyte death and heart dysfunction. Circ Res. 2020;126:456\u201370.","journal-title":"Circ Res"},{"key":"8868_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s10020-024-00948-y","volume":"30","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wang S, Zhang H, Yang X, Ren X, Wang L, et al. Drp1 acetylation mediated by CDK5-AMPK-GCN5L1 axis promotes cerebral ischemic injury via facilitating mitochondrial fission. Mol Med. 2024;30:173.","journal-title":"Mol Med"},{"key":"8868_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202411235","volume":"12","author":"Y Xi","year":"2025","unstructured":"Xi Y, Tao K, Wen X, Feng D, Mai Z, Ding H, et al. SIRT3-mediated deacetylation of DRP1(K711) prevents mitochondrial dysfunction in Parkinson\u2019s disease. Adv Sci. 2025;12:e2411235.","journal-title":"Adv Sci"},{"key":"8868_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100471","volume":"2","author":"D Huang","year":"2021","unstructured":"Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, et al. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2021;2:100471.","journal-title":"Cell Rep Med"},{"key":"8868_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102544","volume":"58","author":"T Tian","year":"2022","unstructured":"Tian T, Lu Y, Lin J, Chen M, Qiu H, Zhu W, et al. CPT1A promotes anoikis resistance in esophageal squamous cell carcinoma via redox homeostasis. Redox Biol. 2022;58:102544.","journal-title":"Redox Biol"},{"key":"8868_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29137-3","volume":"13","author":"N Jiang","year":"2022","unstructured":"Jiang N, Xie B, Xiao W, Fan M, Xu S, Duan Y, et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat Commun. 2022;13:1511.","journal-title":"Nat Commun"},{"key":"8868_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","volume":"164","author":"CT Hensley","year":"2016","unstructured":"Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, et al. Metabolic heterogeneity in human lung tumors. Cell. 2016;164:681\u201394.","journal-title":"Cell"},{"key":"8868_CR20","doi-asserted-by":"publisher","first-page":"21156","DOI":"10.1021\/acsnano.4c04024","volume":"18","author":"H Lu","year":"2024","unstructured":"Lu H, Tong W, Jiang M, Liu H, Meng C, Wang K, et al. Mitochondria-targeted multifunctional nanoprodrugs by inhibiting metabolic reprogramming for combating cisplatin-resistant lung cancer. ACS Nano. 2024;18:21156\u201370.","journal-title":"ACS Nano"},{"key":"8868_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol cell Biol. 2018;19:121\u201335.","journal-title":"Nat Rev Mol cell Biol"},{"key":"8868_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cell.2016.07.002","volume":"166","author":"S Vyas","year":"2016","unstructured":"Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166:555\u201366.","journal-title":"Cell"},{"key":"8868_CR23","doi-asserted-by":"crossref","unstructured":"Gan Y, Meng D, Lang L, Luo J, Dai P, Chang C, et al. PLA2G16-mediated tetracosatetraenoic acid rewires fatty acid oxidation to impair CD8(+) T cell immune function in promoting breast cancer lung metastasis. Adv Sci. 2025;13:e10224.","DOI":"10.1002\/advs.202510224"},{"key":"8868_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218066","volume":"634","author":"Y Bu","year":"2025","unstructured":"Bu Y, Chen D, Li J, Yang R, Gao J, Qu W, et al. STAT3 induced BRD9 activation promotes intrahepatic cholangiocarcinoma progression by enhancing CD36 controlled fatty acid metabolism. Cancer Lett. 2025;634:218066.","journal-title":"Cancer Lett"},{"key":"8868_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126915","volume":"5","author":"M Yu","year":"2019","unstructured":"Yu M, Nguyen N, Huang Y, Lin D, Fujimoto T, Molkentine J, et al. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight. 2019;5:e126915.","journal-title":"JCI Insight"},{"key":"8868_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s43018-023-00563-6","volume":"4","author":"PK Parida","year":"2023","unstructured":"Parida PK, Marquez-Palencia M, Ghosh S, Khandelwal N, Kim K, Nair V, et al. Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases. Nat Cancer. 2023;4:893\u2013907.","journal-title":"Nat Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08868-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:13:19Z","timestamp":1785517999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08868-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8868"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08868-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of [ZJCLA-IACUC-24020017] for the use of animals and conducted in accordance with the National Institutes of Health Laboratory Animal Care and Use Guidelines. Written informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article. All procedures performed in studies involving human participants were in accordance with the standards upheld by the Ethics Committee of Shengjing Hospital of China Medical University (Approval no. 2024PS1817K) and with those of the 1964 Helsinki Declaration and its later amendments for ethical research involving human subjects.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors have obtained written informed consent for publication of the images from a legally authorized representative(s) for anonymized patient information to be published in this article.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"661"}}